Help your patients utilize their time while infusing
Infusing FEIBA [Anti-Inhibitor Coagulant Complex] with a syringe pump helps your patients control the infusion rate and provides a hands-free experience.1
Maximum injection or infusion rate must not exceed 10 units per kg of body weight per minute.
Store at room temperature. Do not exceed 25°C (77°F)
Store FEIBA [Anti-Inhibitor Coagulant Complex] in its original package to protect it from light
Avoid freezing, which may damage the diluent vial
BAXJECT® II Hi-Flow Needleless Transfer Device for easy mixing
To make reconstitution safe, fast, and easy,* FEIBA comes packaged with the BAXJECT II Hi-Flow Needleless Transfer Device. Reconstitution with the BAXJECT II Hi-Flow device requires fewer steps than the previous BAXJECT device, and it is color-coded for more intuitive reconstitution.1,4
Connect the diluent vial
Connect the FEIBA vial
Withdraw mixed FEIBA
*As compared to needles, the BAXJECT II Hi-Flow device is needleless and has a one-piece design.
BAXJECT II Hi-Flow Product Information
Rx only. For safe and proper use of this device, please refer to the Instructions for Use in the FEIBA full Prescribing Information.
NOTE: The BAXJECT II Hi-Flow device should be used only with FEIBA.
The BAXJECT II Hi-flow device is intended for use with a single vial of product and is for single use only. Therefore, reconstitution and withdrawing a second vial into the syringe requires a second BAXJECT II Hi-flow device.
We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies.
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:
Control and prevention of bleeding episodes
Detailed Important Risk Information
WARNING: EMBOLIC and THROMBOTIC EVENTS
Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,
Indications for FEIBA
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:
Control and prevention of bleeding episodes
Perioperative management
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
FEIBA is not indicated for the treatment of bleeding episodes resulting from...
Detailed Important Risk Information
WARNING: EMBOLIC and THROMBOTIC EVENTS
Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;
You are now navigating away from feiba.com
By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Notice may not apply. We encourage you to read the Privacy Policy of every website you visit.
![FEIBA [Anti-Inhibitor Coagulant Complex]. Please see Detailed Important Risk Information, including BOXED WARNING on Embolic and Thrombotic events and full PI.](/us/content/dist/images/Hcp/logo.webp){kind=logo}
